Loading…
Liminatus Pharma, Inc. is projected to rise to $0.159 by 2027, a +40% move from its current price of $0.1137. LIMN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.1059 | $0.1137 | $0.122 | -0.03% |
| Aug 6 | $0.1028 | $0.1136 | $0.1256 | -0.06% |
| Aug 7 | $0.1005 | $0.1136 | $0.1284 | -0.09% |
| Aug 8 | $0.0986 | $0.1136 | $0.1308 | -0.12% |
| Aug 9 | $0.0969 | $0.1135 | $0.133 | -0.14% |
| Aug 10 | $0.0955 | $0.1135 | $0.135 | -0.17% |
| Aug 11 | $0.0941 | $0.1135 | $0.1368 | -0.20% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.0941 | $0.1135 | $0.1368 | -0.20% |
| Week 2 | $0.0869 | $0.1132 | $0.1475 | -0.40% |
| Week 3 | $0.0817 | $0.113 | $0.1562 | -0.60% |
| Week 4 | $0.0776 | $0.1128 | $0.1639 | -0.80% |
| Week 5 | $0.0741 | $0.1126 | $0.171 | -1.00% |
| Week 6 | $0.0711 | $0.1123 | $0.1776 | -1.20% |
| Week 7 | $0.0684 | $0.1121 | $0.1839 | -1.40% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Liminatus Pharma, Inc. is a pre-clinical stage biopharmaceutical company that engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer.
The company was founded in 2018 and is based in Cerritos, California. It is categorized in Healthcare and operates within the healthcare sector focused on oncology research and development.
Liminatus Pharma is a small-cap biotechnology firm that conducts its operations in the United States, pursuing cancer therapies and related biologics as part of its core development program.
The asset LIMN is currently priced at $0.1029 with a market cap of $6.36M and a rank of 5026. These figures place LIMN among small-cap biotechnology listings with a focused early-stage pipeline.
Near-term and multi-year price forecasts show a path of incremental upside from 2026 through 2050, with bullish sentiment resuming after 2026 and continuing through 2050. The forecasted range suggests potential upside to a higher average price by 2027 and beyond, contingent on external factors and execution milestones.
A major floor 40.5% below — a decisive break under it would weaken the trend.
The nearest floor, 12.9% below — buyers have tended to step in here.
The nearest ceiling, 30.2% above — a clean break opens room to run.
A major ceiling 116.4% above — clearing it would confirm fresh momentum.
Key LIMN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LIMN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.1036 | Buy | $0.1052 | Buy |
| MA 10 | $0.1104 | Buy | $0.1091 | Buy |
| MA 20 | $0.1168 | Sell | $0.1144 | Sell |
| MA 50 | $0.132 | Sell | $0.14 | Sell |
| MA 100 | $0.167 | Sell | $0.2977 | Sell |
| MA 200 | $0.5111 | Sell | $1.13 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 41.84 | Neutral |
| Stoch RSI (14) | 21.16 | Neutral |
| CCI (20) | -91.44 | Neutral |
| Williams %R (14) | -97.83 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -10.43 | Sell |
| Bollinger %B (20,2) | 0.23 | Neutral |
| Stochastic %K (14) | 2.17 | Buy |
| TRIX (15) | -0.72 | Sell |
| Awesome (5,34) | -0.01 | Sell |
| Ultimate (7,14,28) | 28.94 | Buy |
| Momentum (10) | -0.02 | Sell |
| Aroon Osc (25) | 56.00 | Buy |
| Hull MA (9) | 0.10 | Buy |
| ADX (14) | 15.22 | Neutral |
| ATR (14) | 0.01 | Info |
Technical sentiment is NEUTRAL with RSI(14) at 40. The 50-day simple moving average sits at $0.1385 while the 200-day moving average stands at $0.5387.
Key support is listed at $0.099 and resistance at $0.148. The 30-day price range spans from $0.0611 to $0.1733, reflecting notable volatility in a short window.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.099 | $0.1137 | $0.1591 | 0% | Neutral | |
| $0.1126 | $0.159 | $0.2433 | +40% | Bullish | |
| $0.1227 | $0.1864 | $0.3064 | +64% | Bullish | |
| $0.1086 | $0.1756 | $0.3048 | +54% | Bullish | |
| $0.0989 | $0.1695 | $0.3075 | +49% | Bullish | |
| $0.0806 | $0.1457 | $0.2747 | +28% | Bullish | |
| $0.0785 | $0.1495 | $0.2914 | +31% | Bullish | |
| $0.0832 | $0.1668 | $0.3349 | +47% | Bullish | |
| $0.0849 | $0.1789 | $0.3692 | +57% | Bullish | |
| $0.1079 | $0.2387 | $0.5051 | +110% | Bullish | |
| $0.0924 | $0.2054 | $0.4725 | +81% | Bullish | |
| $0.2052 | $0.4561 | $1.05 | +301% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.099 | $0.1137 | $0.1477 | +0.00% |
| September 2026 | $0.0992 | $0.1216 | $0.1561 | +6.93% |
| October 2026 | $0.0889 | $0.1108 | $0.1455 | -8.90% |
| November 2026 | $0.0845 | $0.1067 | $0.1427 | -3.68% |
| December 2026 | $0.0916 | $0.117 | $0.1591 | +9.71% |
Click any year to see its month-by-month LIMN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Liminatus Pharma, Inc.'s 2026 outlook centres on $0.1137, within a $0.099 to $0.1591 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, LIMN could reach as high as $0.2433, with a base case around $0.159 and support toward $0.1126 — roughly +40% from $0.1137. Momentum favours further upside here.
Expect LIMN to range from $0.1227 to $0.3064 through 2028. The $0.1864 average target implies a +64% move from current prices. That is up +17% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The LIMN price prediction for 2029 points to an average of $0.1756 (low $0.1086, high $0.3048) — a potential gain of +54% on today's $0.1137. Momentum favours further upside here.
In 2030, LIMN is projected to trade between $0.0989 and $0.3075, averaging $0.1695 — a potential gain of +49% from today's $0.1137. That is -3% versus the projected 2029 average. Buyers look set to stay in control over this stretch.
Liminatus Pharma, Inc.'s 2031 outlook centres on $0.1457, within a $0.0806 to $0.2747 range. That is -14% versus the projected 2030 average. That marks a +28% change versus current levels. Momentum favours further upside here.
By 2032, LIMN could reach as high as $0.2914, with a base case around $0.1495 and support toward $0.0785 — roughly +31% from $0.1137. Buyers look set to stay in control over this stretch.
Expect LIMN to range from $0.0832 to $0.3349 through 2033. The $0.1668 average target implies a +47% move from current prices. That is up +12% on the projected 2032 average. Momentum favours further upside here.
The LIMN price prediction for 2034 points to an average of $0.1789 (low $0.0849, high $0.3692) — a potential gain of +57% on today's $0.1137. Buyers look set to stay in control over this stretch.
In 2035, LIMN is projected to trade between $0.1079 and $0.5051, averaging $0.2387 — a potential gain of +110% from today's $0.1137. That is up +33% on the projected 2034 average. Momentum favours further upside here.
Liminatus Pharma, Inc.'s 2040 outlook centres on $0.2054, within a $0.0924 to $0.4725 range. That is -14% versus the projected 2035 average. That marks a +81% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, LIMN could reach as high as $1.05, with a base case around $0.4561 and support toward $0.2052 — roughly +301% from $0.1137. Momentum favours further upside here.
Investing $1,000 in LIMN today (≈ 8,795.074758 LIMN) could be worth
$4,011.12
+$3,011.12 (+301%) by 2050 · US Dollar
Based on the average projected LIMN price of $0.46 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LIMNwould be worth at today's price.
$1,000 invested in LIMN on Jul 31, 2025 (≈ 159.489634 LIMN) would be worth
$18.13
-$981.87 (-98.2%) today · 0.02× · US Dollar
Based on a LIMN entry price of $6.27 vs. today's $0.1137.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.111 | $1,024.32 | +2.4% |
| 1 month ago | $0.115 | $988.7 | -1.1% |
| 3 months ago | $0.205 | $554.63 | -44.5% |
| 6 months ago | $0.571 | $199.12 | -80.1% |
| 1 year ago | $6.27 | $18.13 | -98.2% |
| All time (1.2y) ago | $8.04 | $14.14 | -98.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LIMN forecast.
Our base-case forecast reaches $0.23 around 2035.
Implied market cap at $0.23: $14.21M
The year-by-year forecast shows a path from 2026 to 2050 with rising averages and sizable upside potential. In 2026, the min, avg, and max are $0.099, $0.1029, and $0.1473 respectively, with ROI of 0; sentiment is NEUTRAL. From 2027 onward, the outlook becomes bullish, with 2027 avg $0.1427 and 2028 avg $0.1705, ROI 38.7% and 65.7% respectively.
By 2030, the avg is $0.1504 with a max of $0.2741 and ROI 46.2%.
The forecast continues to show bullish momentum through 2035 and beyond, with 2035 avg $0.2182 and max $0.4638 (ROI 112%). Notably, 2040 presents an avg of $0.1885 and max $0.4335 (ROI 83.2%), and 2050 projects a min $0.1872, avg $0.4159, max $0.9565 (ROI 304.2%). The annualized volatility is reported at 200%, underscoring high risk and substantial price swings typical of early-stage biotech assets.
Driver and risk factors include the early clinical-stage nature, small-cap status (rank 5026), and sensitivity to clinical trial outcomes and regulatory milestones.
Tap a question to reveal the answer.
The forecast lists for 2030: min $0.0873, avg $0.1504, max $0.2741, ROI 46.2%, sentiment BULLISH.
Forecast shows bullish sentiment from 2027 onward with rising averages (e.g., 2027 avg $0.1427, 2028 avg $0.1705, 2029 avg $0.1593) and a long-run projection to 2050 avg $0.4159 with ROI 304.2%. However, these are estimates and come with high volatility (annualized 200%). Use caution given micro-cap status and clinical-stage risk.
Yes. The 2050 max forecast is $0.9565, which exceeds $0.50, indicating potential to trade above that level under the forecasted scenario.
Current price is $0.1029 and market cap is $6.36M.
The asset has an annualized volatility of 200% and a micro-cap ranking (5026), reflecting high volatility and sensitivity to clinical-stage development milestones and regulatory outcomes.
Liminatus Pharma, Inc. Community Discussion
0Share your Liminatus Pharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.